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Abstract
Purpose Apart from binding to the dopamine transporter
(DAT), [123I]FP-CITshows moderate affinity for the serotonin
transporter (SERT), allowing imaging of both monoamine
transporters in a single imaging session in different brain
areas. The aim of this study was to systematically evaluate
extrastriatal binding (predominantly due to SERT) and its age
and gender dependencies in a large cohort of healthy controls.
Methods SPECT data from 103 healthy controls with well-
defined criteria of normality acquired at 13 different imaging
centres were analysed for extrastriatal binding using volumes
of interest analysis for the thalamus and the pons. Data were
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examined for gender and age effects as well as for potential
influence of striatal DAT radiotracer binding.
Results Thalamic binding was significantly higher than pons
binding. Partial correlations showed an influence of putaminal
DAT binding on measured binding in the thalamus but not on
the pons. Data showed high interindividual variation in
extrastriatal binding. Significant gender effects with 31 %
higher binding in women than in men were observed in the
thalamus, but not in the pons. An age dependency with a
decline per decade (±standard error) of 8.2±1.3 % for the
thalamus and 6.8±2.9 % for the pons was shown.
Conclusion The potential to evaluate extrastriatal predomi-
nant SERT binding in addition to the striatal DAT in a single
imaging session was shown using a large database of [123I]FP-
CIT scans in healthy controls. For both the thalamus and the
pons, an age-related decline in radiotracer binding was ob-
served. Gender effects were demonstrated for binding in the
thalamus only. As a potential clinical application, the data
could be used as a reference to estimate SERT occupancy in
addition to nigrostriatal integrity when using [123I]FP-CIT for
DAT imaging in patients treated with selective serotonin re-
uptake inhibitors.
Keywords Dopamine transporter . Serotonin transporter .
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Introduction
Imaging of the dopaminergic system provides a valuable tool
for discriminating neurodegenerative Parkinsonian syn-
dromes with an associated presynaptic dopaminergic deficit
from diseases without presynaptic neurodegeneration (e.g.
essential tremor) [1–3]. The use of dopamine transporter
(DAT) SPECT has recently been extended to the discrimina-
tion between patients with suspected dementia with Lewy
bodies (DLB) and those with Alzheimer’s disease [4].
[123I]N-ω-Fluoropropyl-2β-carbomethoxy-3β-(4-
iodophenyl)nortropane ([123I]FP-CIT) is the most widely used
radiotracer for DAT imaging. It is commercially available and
approved for use in patients with Parkinsonian syndromes
(Europe and the US) and suspected DLB (Europe). [123I]FP-
CIT shows high affinity for DAT but also moderate affinity for
the serotonin transporter (SERT) [5]. Binding of radiolabelled
tropane derivatives in most extrastriatal regions (ESTR) has been
primarily attributed to SERT binding. The thalamus has about 20
times more SERT than DAT binding sites [6–8]. In an autoradi-
ography study of the human brain [9], the selective serotonin
reuptake inhibitor (SSRI) citalopram almost entirely displaced
[125I]RTI-55 ([125I]2β-carbomethoxy-3β-(4-iodophenyl)tropane,
[125I]β-CIT) in the midbrain, thalamus and hypothalamus, indi-
cating that radiotracer uptake in these regions is almost exclusive-
ly associated with SERTand not with DAT.With a preference for
DAT sites (3.5 nM) over SERT sites (10 nM) [5], approximately
70 % of [123I]FP-CIT uptake in the thalamus should result from
SERT binding. Consistently, applied to SPECT imaging, Ziebell
et al. [10] observed a loss of thalamic binding potential of the
nondisplaceable radioligand by 63 % when blocking SERTwith
citalopram. For semiquantitative evaluation using a ratio method
in transient equilibrium (as generally applied in clinical routine),
even 86 – 90 % of thalamus signal could be attributed to SERT
binding [10, 11]. The first successful attempts to establish
[123I]FP-CIT for SERT imaging studied the central serotonergic
system in 6 [12] and 19 [13] healthy volunteers. Initial applica-
tions in patients indicated potential clinical usefulness showing
reduced extrastriatal SERT availability in patients with
Parkinson’s disease and particularly in those with DLB [14, 15].
In comparison to other cocaine analogues suitable for
SPECT imaging, [123I]FP-CIT allows the combined evalua-
tion of both DAT and SERT in a single scan. The ideal time
window for imaging the extrastriatal SERT is between 2 and
3 h after injection [13]. For DAT imaging with [123I]FP-CIT,
the pseudoequilibrium is reached 3 h after injection [16],
resulting in ideal imaging conditions for both monoamine
transporters 3 h after injection. This, in addition to its wide-
spread availability, makes [123I]FP-CIT attractive for imaging
not only the striatal DAT but also the extrastriatal SERT in the
diagnostic work-up of patients. As a potential clinical appli-
cation, SERToccupancy could be estimated in patients treated
with SSRIs undergoing DAT SPECT to measure nigrostriatal
integrity. Depression is a common nonmotor symptom in
Parkinson’s disease and its treatment is challenging [17].
Higher pretreatment SERT availability, higher SSRI-induced
occupancy of SERT [18] and SERT interplay between the
median raphe nucleus and projection areas [19] have been
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associated with treatment response. Knowledge of SERT
availability could allow individualization of treatment strate-
gies (for example by optimized selection of the most suitable
antidepressant with a serotonergic, noradrenergic, dopaminer-
gic or monoamine oxidase inhibiting mechanism).
For accurate interpretation of [123I]FP-CIT binding to SERT,
knowledge of potential influencing factors such as age or
gender dependencies is essential. An age-related decline in
SERT binding has been described using other radioligands
[20–27]. However, post-mortem studies have not confirmed
effects of aging on SERT mRNA availability [28–32].
The aim of this study was to explore age and gender
influences on extrastriatal binding of [123I]FP-CIT to SERT
in healthy volunteers using the data from a well-defined
cohort of a large multicentre trial.
Methods
Subjects
Included in this prospective study were 103 healthy individuals
free of neurological and psychiatric diseases (46 women, 57
men; age range 21 – 83 years, mean 51.8±17.8 years). The study
population is part of the ENC-DAT (European Normal Control
Database of DaTSCAN) database established as an initiative of
the Neuroimaging Committee of the European Association of
Nuclear Medicine and includes data from 13 different imaging
centres. All subjects had to fulfil predefined criteria of normality
without any significant clinical abnormalities in medical history,
blood chemistry, neurological examination (including the
Unified Parkinson’s Disease Rating Scale score) and psychiatric
evaluation including the Symptom Checklist-90 revised (score
<63) [33] and the Beck Depression Inventory (score <9) self-
assessment scales [34]. Cognitive deficits as assessed by the
Mini-Mental State Examination (score ≥28) were ruled out.
Furthermore, a history of Parkinsonian syndromes in first-
degree relatives was an exclusion criterion. The study population
had a balanced gender and age distribution. The average ages
were comparable between the women (51.3±17.7 years) and the
men (52.1±18.1 years).
Each subject underwent MRI examination according to the
protocols of the respective imaging centre to detect potential
structural pathologies. Pregnancy was ruled out in the women
by urinary pregnancy testing. In addition, all subjects underwent
urine drug testing. Approval of the ethics committee and the local
authorities was obtained and all subjects signed written informed
consent. Further details have been reported previously [35].
SPECT imaging
Stringent quality control protocols were applied at each of the
13 imaging sites [36]. Uniformity and centre of rotation were
continuously maintained. In addition, 123I SPECT images of
an anthropomorphic striatal phantom (Radiology Support
Devices Inc., Long Beach, CA) were acquired in each of the
participating centres according to a protocol published else-
where [37] to calibrate the gamma camera systems on 17
imaging systems: four Siemens ECAM, three GE Infinia,
three Philips IRIX, two Siemens SYMBIA, two Trionix
Triad XLT 20, one GE Millennium VG, one Siemens
MultiSPECT, and one Mediso x-Ring/4HR.
[123I]FP-CIT (180±16MBq) was injected intravenously as
a bolus. SPECT images were acquired 3.0±0.3 h after tracer
injection. Acquisition parameters were: fixed rotational radius
between 13 and 15 cm, matrix 128 × 128, angular sampling
≤3° (360° rotation), and hardware zoom of 1.23 to 2.00 to
achieve a pixel size of 2 – 3 mm. The photopeak was set to
159 keV ±10 %. The acquisition time was chosen to obtain at
least 2 million counts per study. Further information on
SPECT system configuration and the scanning procedure
has been reported previously [35].
In the subset of the ENC-DAT database reported
here, scans were reconstructed using HERMES hybrid
reconstruction (Hermes Medical Solutions, Stockholm,
Sweden) using ordered subsets expectation maximization
(OSEM) with 16 iterations and four or five subsets
depending on the number of projections. To obtain a
high level of standardization of scans with different
camera systems and to reduce partial volume effects
when evaluating small structures such as the pons, all
scans were corrected for
1. Attenuation: Chang method [38] with automatically gen-
erated ellipses, and an attenuation coefficient μ of 0.146
has been used, the high value for μ corresponding to the
“narrow beam attenuation coefficient” that is recommend-
ed when scatter correction is applied [39].
2. Scatter: A Monte-Carlo based scatter correction was ap-
plied using the HERMES Monte Carlo simulator [40].
Basically this method uses reconstruction-based scatter
compensation with Monte Carlo modelling of scatter. It
includes the simulation of the pathways of a large number
of photons accelerated by a coarse grid and intermittent
scatter modelling without simulation of septal penetration.
3. Resolution recovery: Correction for depth-dependent de-
tector response was done separately for each camera
model using calculated point-spread functions based on
the exact geometry of the respective collimator as well as
the scanning geometry of the detector orbit [41].
Three-dimensional gaussian postfiltering was applied
using a kernel with full-width at half-maximum (FWHM) of
7 mm, resulting in an estimated image FWHM of approxi-
mately 8 – 10mm (more details are provided by Dickson et al.
[36]).
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Automated semiquantitative evaluation method
Semiquantitative evaluation of the SPECT data was per-
formed using the brain analysis software (BRASS, version
3.6; Hermes Medical Solutions, Stockholm, Sweden). The
software automatically performs spatial coregistration of indi-
vidual patient images to a [123I]FP-CIT healthy control tem-
plate using a registration algorithm based on mutual informa-
tion and optimized for [123I]FP-CIT images. The accuracy of
the coregistration of scans to the template was confirmed in all
subjects. The template itself was derived using the 103 normal
control scans, which were spatially normalized to the
Montreal Neurological Institute standard MRI template
(MNI; McGill University, Montreal QC, Canada) [42]. Next,
a standard set of 3-D VOIs defining the thalamus and the
putamen based on the Automated Anatomical Labelling
(AAL) atlas [43] as well as a spherical VOI for the pons was
created. An occipital cortex (OC) VOI served as the reference
region. The respective VOIs are shown in Fig. 1. All VOIs
were applied to the SPECT data, and manually adjusted (drag
and drop) when necessary to ensure positional accuracy. The
pons VOI was positioned to cover the uptake in the area of the
raphe nuclei. Mean counts per voxel were calculated for each
VOI. Specific binding (SB) ratios in the predefined ESTR in
relation to the OC were calculated according to the formula:
SB ¼ ESTR OC
OC
Statistics
Descriptive statistics are given as means and standard devia-
tion. Comparisons between and within groups were tested
with independent group or paired Student's t tests, respective-
ly. The relationship between age and SERT binding was
analysed using linear regression and described by Pearson
correlation coefficients. To verify differences in the slopes of
the linear regression curves between male and female subjects
and therefore different gender profiles of age effects, the effect
of gender on the slopes of the regression lines was tested by
analysis of covariance investigating the significance of
the interaction between the classification effect (gender)
and the covariate (measured SB). Analyses of covari-
ance was used to determine the influence of gender, age
Fig. 1 VOIs used for
semiquantitative analysis and
corresponding SPECT template
(left column colour scale
thresholds adjusted to depict the
respective structures)
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and striatal binding on extrastriatal binding. To control
for confounding factors, partial correlations were calcu-
lated. All statistical analyses were performed using
SPSS software version 13.0 (SPSS Inc, Chicago, IL).
Results
The age distributions of the men and women were balanced
(p=0.814). Measured specific SERT binding ratios in both the
thalamus and pons showed considerable variability across the
full age range (Fig. 2) with thalamic binding ratios in general
being significantly higher than pons binding ratios (0.35±0.17
vs. 0.26±0.21, p=0.001).
Mean SB ratios in the thalamus were significantly higher in
women than in men (0.40±0.15 vs. 0.31±0.17, p=0.003). Mean
SB ratios in the pons were slightly higher in men than in women
(0.29±0.19 vs. 0.22±0.23), but this difference did not reach the
level of significance (p=0.077). A linear fit showed an age-
related decline in [123I]FP-CIT binding ratios in both the thala-
mus and the pons (Fig. 2). The corresponding regression param-
eters, Pearson correlation coefficients and p values are given in
Table 1 (for comparison these values are also given for the
putamen). Correlation coefficients were stronger for the thalamus
than for the pons. Correlations were significant for the entire
cohort as well as for men and women, with only one exception:
the correlation between age and SB ratios in the pons in women
failed to reach the level of significance. Extrastriatal binding
ratios showed a reduction with normal aging with average
(±standard error) declines per decade of 8.2±1.3 % in the thal-
amus and 6.8±2.9 % in the pons.
The declines in binding ratios per decade in the thalamus
and in the pons were not different between men (thalamus 9.0
±1.9 %, pons 7.9±2.7 %) and women (thalamus 7.1±1.6 %,
analysis of covariance p=0.61; pons 4.3±7.0 %, p=0.10).
Specific thalamic binding ratios were also correlated with
putaminal binding ratios (Pearson’s correlation coefficient
0.35, p<0.001), whereas no correlation was found between
pons and putaminal binding ratios (correlation coefficient
0.11, p=0.29; Fig. 3). Controlling for putaminal binding ratios
with partial correlations, age effects remained stable in both
the thalamus (p<0.001) and pons (p=0.043).
Discussion
To our knowledge this is the largest study to systematically
evaluate extrastriatal binding of the commercially available
DAT tracer [123I]FP-CIT in a cohort of healthy controls with a
wide age range and with well-defined criteria of normality. The
study population had balanced age distribution across the whole
age range as well as an even gender distribution. The measured
specific thalamic [123I]FP-CIT binding ratios were similar to
those recently reported by Borgers et al. [12] and Koopman
et al. [13]. As expected, SB ratios in SERT-rich ESTR were
considerably lower than in the DAT-rich striatum, owing to the
lower affinity of [123I]FP-CIT for SERT than for DAT [5, 44]
and the overall lower expression of SERT in the brainstem and
thalamus in comparison to the striatal DATexpression [45, 46].
There was high variability (high standard deviation com-
pared to the average) of extrastriatal radiotracer binding across
the entire age range. A drug-induced reduction due to poten-
tial blocking effects of SSRIs [10, 11] or other psychotropic
drugs were excluded as all subjects were drug-naive and urine
drug screening revealed no abnormalities. Also psychiatric
disorders as potential confounding factors were ruled out. In
line with our results, similar high interindividual variations in
extrastriatal binding have also been found using other SPECT
and PET tracers [10, 13, 47–50]. Ziebell et al. [10] discussed
potential reasons for this variability. It could be attributed to
Fig. 2 Correlations between age and [123I]FP-CIT binding ratios in (a)
the thalamus and (b) the pons
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variation in SERT density, the relatively low [123I]FP-CIT
binding affinity to SERT with consequently relatively low
binding ratios, or relative DAT versus SERT density ratios in
the analysed regions.
We observed a significant correlation between thalamic
(but not pons) radiotracer binding and putaminal binding. A
similar finding was reported by Ryding et al. [26] for the
thalamus using ([123I]β-CIT). Visual image analysis revealed
potential spill-in of striatal counts into the thalamic VOI.
Despite applying resolution modelling and scatter correction,
spill-in of counts cannot be entirely eliminated [51] and might
have led to a stronger observed correlation than could be
attributed to direct thalamic DAT radiotracer binding, since
DAT density in the thalamus is known to be relatively low
[52]. Potential spill-in might limit the specific analysis of
SERT in the thalamus and (apart from potential biological
binding differences, partial volume effects and VOI sizes)
could also contribute to the higher radiotracer uptake observed
in the thalamus than in the pons. Eventually this might also
account for the significantly higher thalamic uptake in women
than in men, due to the well-documented gender dependency
of DAT binding [53, 54]. Borgers et al. [12] analysed binding
of [123I]FP-CIT in the hypothalamus in healthy controls, pa-
tients with pituitary insufficiency and patients with hypotha-
lamic impairment, but found no differences in binding ratios
in the hypothalamus among these groups, although SERT
appears to play a key role in the hypothalamus [55]. The
assumed spill-in of counts from striatal DAT binding in com-
bination with the overall low specific [123I]FP-CIT binding
ratios in the thalamus may have eventually masked the ex-
pected group differences. In our subjects, the pons region did
not appear to be influenced by striatal binding. Although
higher radiotracer binding in women than in men has been
reported in this region for other radiotracers [53, 56], and
despite preclinical evidence of protective effects of oestrogens
on SERT [57], we were not able to show significant gender
effects on [123I]FP-CIT binding. We found a significant age
dependency of [123I]FP-CIT binding in both the thalamus and
the pons. These age effects remained significant after
controlling for potential spill-in from the putamen using par-
tial correlation analyses.
Post-mortem studies with [3H]imipramine [29–31] and
[3H]paroxetine [28, 32] did not reveal any age-dependent
Table 1 Parameters of linear re-
gression analysis of age with tha-
lamic, pons and putaminal (for
comparison) radiotracer binding
ratios for the entire cohort as well
as for the subgroups men and
women
Region Gender Slope ± standard error Constant Pearson coefficient p value
Thalamus Both −0.0050±0.0008 0.61±0.04 −0.526 <0.001
Female −0.0045±0.0010 0.64±0.06 −0.547 <0.001
Male −0.0052±0.0011 0.58±0.06 −0.542 <0.001
Pons Both −0.0027±0.0012 0.40±0.06 −0.226 0.022
Female −0.0012±0.0020 0.28±0.11 −0.092 0.542
Male −0.0040±0.0013 0.50±0.07 −0.369 0.005
Putamen Both −0.0110±0.0022 2.70±0.12 −0.439 <0.001
Female −0.0131±0.0034 2.85±0.18 −0.386 0.003
Male −0.0093±0.0030 2.58±0.17 −0.503 <0.001
Fig. 3 Correlations between putaminal [123I]FP-CIT binding ratios and
(a) thalamic binding ratios and (b) pons binding ratios
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decline in SERT expression in the thalamus or brainstem. The
inability of these studies to demonstrate age-dependency
could potentially be explained by their limited sample size,
low age range of the subjects and limited selectivity of the
ligands used. Most neuroimaging studies have confirmed
effects of healthy aging on SERT. Using [123I]β-CIT, several
studies have shown a decline in thalamus binding per decade
in the range 3.2 % to 7.2 % and in midbrain binding in the
range 4.2 % to 8.3 % [22, 25, 27]. We obtained higher values
(8.6 % in the thalamus and 7.1 % in the pons) which lie in a
similar range to those reported for DAT [58–61]. Binding loss
with healthy aging seems to vary depending on which radio-
tracer is used (possibly attributable to different levels of spe-
cific to nonspecific binding as well as the contribution of
SERT to the reference region used). Using the more SERT-
selective tracer 2-((2-((dimethylamino)methyl)phenyl)thio)-
5-[123I]iodophenylamine ([123I]ADAM), a low decline of only
3.0 % per decade in the midbrain was reported by Newberg
et al. [24] and using [123I]2β-carbomethoxy-3β-(4-
iodophenyl)nortropane ([123I]Nor-β-CIT) a decline of 2.0 %
per decade was reported by Kuikka et al. [23]. In young
subjects up to 35 years of age, Buchert et al. found no relevant
influence of aging on SERT [56] using [11C]McN5652 and
PET. Aging effects in young subjects appear not to be rele-
vant. On the other hand, the finding could also indicate a
nonlinear relationship between age and SERT binding that
cannot be entirely ruled out based on our data. Nonlinear fits
did not provide usable results in our study population due to
the observed high variation of extrastriatal binding.
There are some limitations to consider when interpreting
our results. First, [123I]FP-CIT has higher affinity to DAT than
to SERT [5, 44]. There is evidence of the presence of some
DATexpression in the midbrain [62], potentially also resulting
in a small influence on the pons binding observed. We con-
trolled for this statistically using partial correlations. Age
effects remained stable when controlling for DAT binding
ratios measured in the putamen. For [123I]β-CIT, attempts
have been made to separate DAT and SERT binding based
on the different uptake kinetics and on SERT blocking with
selective SSRI [26]. Using this method, Ryding et al. observed
no age dependency of SERT binding, but the sample size (23
healthy controls) is considerably lower than in our study.
More accurate separation could be achieved using more se-
lective SERT ligands such as [123I]ADAM [63]. Second, our
results were based on a variety of different imaging equip-
ment, potentially explaining some of the interindividual vari-
ation observed. Phantom calibration [37] was validated for
striatal DAT binding only, and not for extrastriatal SERT-rich
regions. However, extensive efforts for standardization of
acquisition protocols and camera-specific resolution model-
ling in the reconstruction process were made, and all scans
were processed and evaluated in a single centre. Third, apart
from resolution modelling in the reconstruction process, no
additional MRI-based recovery correction was performed to
reduce potential pons atrophy effects with aging. Previous
studies examining age-related volumetric decline in the
brainstem, however, have shown no overall volume loss in
this area [64, 65].
Fourth, we did not correct for other potential confounding
factors such as seasonal variability in SERT availability [56].
Also polymorphism in the SERT promoter gene has been
reported, that can potentially regulate SERT expression [66]
possibly modulated by a family history of axis-I disorders. A
family history of axis-I disorders was an exclusion criterion.
Fifth, in line with most other groups, we used the OC as the
reference region for both SERT and DAT analysis which
contains a low (but presumably not relevant) concentra-
t ion of SERT [45, 67]. Age effects could be
underestimated if age-related decline in the occipital
reference region occurs in a similar proportion as in
the thalamus or pons. We did not use the cerebellum
as the reference region, since attenuation correction in
this area is problematic and would have introduced
additional variability. In addition, in clinical routine
imaging, the cerebellum is often not covered entirely,
limiting the use of a cerebellar reference region.
Conclusion
Imaging with the radioligand [123I]FP-CIT, that is com-
mercially widely available and approved for specific
applications, may allow the evaluation of DAT and
SERT in a single imaging session. [123I]FP-CIT binding
in the thalamus as well as in the pons showed high
interindividual variation most likely hampering accurate
interpretation of SERT expression on an individual ba-
sis. The additional information on SERT binding, how-
ever, may provide new insights into neurological and
psychiatric diseases such as shown for Parkinson’s dis-
ease and DLB [14, 15] in research trials in which
[123I]FP-CIT and SPECT are used. The data could also
be used as a reference to estimate SERT occupancy in
addition to nigrostriatal integrity when using [123I]FP-
CIT for DAT imaging in patients treated with selective
SSRIs to individualize treatment of depression, a com-
mon nonmotor symptom in Parkinson’s disease.
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